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ARTICLE
DHX9-dependent recruitment of BRCA1 to RNA
promotes DNA end resection in homologous
recombination
Prasun Chakraborty 1 & Kevin Hiom 1✉
Double stranded DNA Breaks (DSB) that occur in highly transcribed regions of the genome
are preferentially repaired by homologous recombination repair (HR). However, the
mechanisms that link transcription with HR are unknown. Here we identify a critical role for
DHX9, a RNA helicase involved in the processing of pre-mRNA during transcription, in the
initiation of HR. Cells that are deficient in DHX9 are impaired in the recruitment of RPA and
RAD51 to sites of DNA damage and fail to repair DSB by HR. Consequently, these cells are
hypersensitive to treatment with agents such as camptothecin and Olaparib that block
transcription and generate DSB that specifically require HR for their repair. We show that
DHX9 plays a critical role in HR by promoting the recruitment of BRCA1 to RNA as part of the
RNA Polymerase II transcription complex, where it facilitates the resection of DSB. Moreover,
defects in DHX9 also lead to impaired ATR-mediated damage signalling and an inability to
restart DNA replication at camptothecin-induced DSB. Together, our data reveal a previously
unknown role for DHX9 in the DNA Damage Response that provides a critical link between
RNA, RNA Pol II and the repair of DNA damage by homologous recombination.
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DNA breaks pose a significant threat to genomic stabilityand if repaired improperly can lead to increased muta-genesis, the generation of harmful chromosome aberra-
tions, and cell death. Defects in the repair of DSB have been linked
with a wide variety of diseases including immunodeficiency, neu-
rodegenerative disease, hematological disease, progeria, and cancer.
DSB are generally repaired by one of two pathways: non-
homologous end-joining, which is error prone and homologous
recombinational repair that is relatively error-free. Although
many of the biochemical steps required in the physical repair of
DSB have been well characterized, the factors that govern the
regulation of these pathways and the genomic context in which
they operate is less well understood. For example, it was recently
demonstrated that while DSB that occur in highly transcribed
regions of the genome are preferentially repaired through HR1,
those in transcriptionally inactive loci are not. However, the
mechanism through which HR is targeted to transcriptionally
active regions of the genome remains unknown.
Interestingly, in addition to the well-characterized range of DNA
binding proteins that are recruited at or near sites of DNA damage,
a variety of RNA binding proteins (RBP) also accumulate at DSB
where they are hypothesized to facilitate DNA repair2. The
recruitment of RBPs is often linked to the generation of a variety of
long and short RNA transcripts in the vicinity of DNA damage as
part of the DNA damage response (DDR)3. While several
hypotheses have been proposed to explain how RNA and RBP
might contribute to the repair of DNA lesions at actively tran-
scribed genes, a consensus mechanism has yet to emerge.
DHX9 is a multifunctional DNA/RNA helicase and a compo-
nent of the RNA polymerase II (RNA Pol II) holoenzyme where it
contributes to co-transcriptional processing of pre-mRNA4.
Efforts to knock out the DHX9 gene in various cell lines using
Crispr/Cas9 have failed and homozygous deletion of DHX9 in
mice results in embryonic lethality5, indicating that its function is
essential. However, cells depleted of DHX9 using siRNAs exhibit
relatively normal viability, suggesting that a residual low level of
DHX9 is sufficient to sustain cell proliferation6.
In addition to its roles in RNA splicing and RNA editing, several
observations point to a role for DHX9 in DNA replication and/or
the maintenance of genome stability. For instance, in cells DHX9
localizes to origins of replication and its suppression in human
diploid fibroblasts leads to blocked replication, P53-mediated
arrested growth, and senescence7. It also interacts with compo-
nents of the DDR such as BRCA18 and Ku869 that are important
for the repair of DNA breaks caused by replication stress.
DHX9 is an SF2 type helicase with functional similarities to the
DExH-box DNA repair helicases BLM and WRN10. Biochemical
studies established that DHX9 binds to single-stranded DNA and
RNA and, like BLM and WRN, unwinds abnormal nucleic acid
secondary structures that form during DNA replication and
transcription6. These substrates include RNA-DNA hybrid, D-loops,
and DNA forks, as well as RNA and DNA guanine quadruplexes
(G4-DNA/RNA)11,12, all of which have the potential to cause
genomic instability. Most recently DHX9 was shown to be required
for resolving large secondary structures that occur in transcripts of
inverted genomic Alu repeats13. Nevertheless, a specific role for
DHX9 in the repair of DNA damage has yet to be established.
Here we demonstrate that DHX9 is a bone fide component of
the DDR and show how it plays a critical role in linking tran-
scription to the repair of DNA breaks by HR.
Results
DHX9 is redistributed in response to DNA damage. Proteins
involved in the DDR are often recruited at or near sites of DNA
damage to form nuclear foci. To establish if DHX9 is a bone fide
DDR protein we investigated whether it also accumulates in
nuclear foci in cells with damaged DNA. To do this we treated
cells with two agents, camptothecin (Cpt) and ionizing radiation
(IR), that introduce DSB into the genome through different
mechanisms (Supplementary Fig. 1). IR introduces DSB into the
genome through the collision of high-energy particles that
directly break the sugar-phosphate backbone of DNA. It also
splits water molecules to create hydroxyl radicals that similarly
attack the DNA backbone to generate both DSB and single-
stranded DNA breaks (SSB). Cpt, on the other hand, inhibits
topoisomerase I (top I) leading to the generation of SSB in which
the 3′ end of the break is covalently attached to top I protein. This
is referred to as a top I cleaved complex (top Icc)14. Replication
forks encountering these lesions are prone to stalling and col-
lapse, converting SSB to DSB. Since top I plays a pivotal role in
the removal of supercoils during transcription, Cpt-induced DSB
are commonly enriched in transcribed regions of the genome.
We treated cells with IR and Cpt and then stained them with a
specific antibody, using fluorescence imaging to determine the
distribution of DHX9 protein in the nucleus. Importantly, we first
confirmed that our antibody was specific for DHX9 by showing
that it detected the protein in cells transfected with a nonspecific
control siRNA but not in cells in which DHX9 was knocked down
using a specific siRNA (Supplementary Fig. 2a).
In cells treated with Cpt, DHX9 accumulated in discreet
nuclear aggregates/foci that were not observed in undamaged cells
(Fig. 1a). Importantly, DHX9 foci colocalized on chromatin with
the phosphorylated form of histone H2AX (γH2AX), confirming
that it is recruited at or near sites of DNA breaks (Fig. 1b). While
DHX9 aggregates were also detected in cells exposed to IR, these
foci did not significantly co-localize with γH2AX (Fig. 1b),
indicating that DHX9 is not recruited equally at all DSB.
Although DHX9 accumulated at DSB in cells that were treated
with Cpt for 30 min, these foci were relatively faint (Supplemen-
tary Fig. 1b). However, DHX9 foci stained more intensely after 2
to 4 h Cpt treatment, suggesting that molecules of DHX9
accumulate at DSB over time. Since DHX9 associates with the
transcription complex we hypothesized that the increased
intensity in DHX9 staining might reflect the accumulation of
stalled RNA polymerase II (RNA Pol II) at DSB. Consistent with
this hypothesis, we found that Cpt-induced DHX9 foci were
greatly diminished in cells that were also treated with the
transcription inhibitor DRB (5,6-dichloro-1-β-D-ribofuranosyl-
benzimidazole) (Fig. 1c). Furthermore, DHX9 foci induced by
both Cpt and IR were disassembled when cells were treated with
RNaseA to degrade RNA (Fig. 1d and Supplementary Fig. 2c, d).
Taken together, these data indicate that DHX9 accumulates at
Cpt-induced DSB through a mechanism that is dependent on
RNA and RNA Pol II transcription. We speculate that the
accumulation of DHX9 in IR-induced foci also reflects stalling of
RNA Pol II, but at lesions other than DSB.
DHX9 has been linked to the metabolism of R-loops that form
during transcription at sites of paused RNA Pol II6,15. Stalling of
RNA Pol II enables the nascent RNA to invade its complementary
duplex DNA, generating a region of DNA-RNA hybrid and a
displaced ssDNA. DNA-RNA hybrid has been hypothesized to
play a role in the repair of DSB through an, as yet, unspecified
mechanism. To determine whether the generation of R-loops was
linked to the formation of DHX9 foci we treated cells with Cpt
and prior to imaging incubated them with RNAseH1 to
specifically degrade DNA-RNA hybrid (Supplementary Fig. 2b,
e). The faint DHX9 foci that formed after 30 min exposure to Cpt
were resistant to treatment with RNaseH1, suggesting that these
early forming foci were not associated with R-loops (Supplemen-
tary Fig. 2b). Intriguingly, the intense DHX9 foci that formed
after two or more hours of exposure to Cpt were greatly
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diminished by RNaseH1 treatment, indicating that DNA-RNA
hybrid was present at these sites (Supplementary Fig. 2e). This
supported our hypothesis that Cpt-induced DHX9 foci develop
over time and that the more intense, later forming DHX9 foci
represent DSB at which stalling of transcription complexes is
associated with the generation of DNA-RNA hybrid. Whether R-
loops contribute to the repair of DSB remains the subject of much
speculation.
To establish whether DHX9 is required for the repair of DSB
we used two different siRNAs to deplete DHX9 protein and
measured the sensitivity of these cells to different DNA damaging
agents (Fig. 2a). Importantly, we first confirmed that knockdown
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of DHX9 did not cause alterations to the cell cycle that might
influence the ability of these cells to repair DNA damage
(Supplementary Fig. 3a). We then showed that depletion of
DHX9 in cells caused hypersensitivity to both Cpt and Olaparib,
an inhibitor of poly-ADP ribose polymerase 1 (PARP1) (Fig. 2b,
c). However, depletion of DHX9 did not sensitize cells to IR-
induced DNA damage (Fig. 2d). This directly mirrored our
experiments showing that DHX9 accumulated at DSB induced by
Cpt but less at IR-induced DSB (above). Importantly, the
hypersensitivity of DHX9 deficient cells to Cpt and to Olaparib
was reversed by expression of wild-type DHX9 from a plasmid
but not the helicase “defective” DHX9 D511A E512A mutant
protein (DHX9dead)16, indicating that the helicase activity of
DHX9 is required in the repair of DNA damage (Fig. 2b, c).
DHX9 is required for homology dependent repair of DNA
breaks. DSB are generally repaired by two major pathways; non-
homologous end joining (NHEJ) and HR. To establish whether
DHX9 contributes to the repair of DSB by these pathways we
used two established GFP-based reporter assays (cell lines H1299-
dA3-117 and U2OS pDR-GFP) that measure the repair of DSB
induced by expression of the restriction endonuclease I-Sce1
(Fig. 3a, b). As expected, siRNA-mediated depletion of the end-
joining proteins Ku86 and p54nrb in H1299-dA3-1 cells caused a
reduction in the repair of I-Sce1 induced DSB by NHEJ, com-
pared to a siRNA control (Fig. 3a). Interestingly, H1299-dA3-1
cells depleted for DHX9 were not only proficient in NHEJ but
exhibited elevated repair of I-Sce1 induced breaks through this
pathway. We hypothesized that the depletion of DHX9 stimulated
NHEJ by inhibiting the repair of DSB through a competing
pathway, most likely HR. Importantly, we confirmed that elevated
NHEJ was specific to the loss of DHX9 in these cells, by showing
that overexpression of a siRNA resistant myc-DHX9 gene from a
plasmid reduced NHEJ to control levels.
On the other hand, knockdown of DHX9 in U2OS cells
containing the pDR-GFP HR reporter led to a 50–70% reduction
in the repair of DSB by HR, compared to wild-type cells (Fig. 3b).
This HR defect was comparable to that of cells deficient for the
key HR mediator protein BRCA1. Critically, HR was restored to
cells that overexpressed a siRNA-resistant myc-DHX9 cDNA
from a plasmid (Fig. 3c). These data confirmed that DHX9 is
required for the repair of DSB by HR and to prevent the
hypersensitivity of cells to agents such as Cpt and Olaparib.
DHX9 promotes DNA end resection. Repair of DSB by HR
requires that broken DNA ends are first resected to generate
regions of ssDNA. Single-stranded DNA ends are protected from
degradation by the binding of the single-strand binding protein
complex RPA, which is subsequently replaced by the RAD51
recombinase to catalyze DNA strand exchange and drive HR. To
determine whether DHX9 is required in these early steps of HR
we treated cells with IR and with Cpt and used fluorescence
imaging to detect γH2AX and RPA as measures of DNA breaks
and DNA end-resection, respectively. Cpt treatment induced
similar levels of γH2AX foci in wild-type cells and in cells
depleted of DHX9, reflecting the generation of equivalent num-
bers of DSB (Fig. 4a and Supplementary Fig. 4a, b). However, cells
that were depleted of DHX9 had many fewer RPA foci than did
wild-type cells, suggesting that DHX9 is required in DNA
resection (Fig. 4b and Supplementary Fig. 3b). We confirmed that
resection was dependent on the helicase activity of DHX9 DNA
by showing that RPA foci were restored to cells in which a wild-
type siRNA-resistant DHX9 cDNA was overexpressed from a
plasmid, but not in cells expressing cDNA encoding the helicase
defective DHX9 D511A/E512A mutant protein (Fig. 4c). Western
blot analysis also confirmed that chromatin-bound RPA was
greatly reduced in cells depleted of DHX9 compared to control
cells (Fig. 4d and Supplementary Fig. 3c). Finally, we used an
established BrdU staining assay to quantify ssDNA by fluores-
cence imaging16. This confirmed that the generation of
ssDNA was significantly impaired in DHX9 defective cells com-
pared to wild type (Supplementary Fig. 3d). Resection of DNA
ends and binding of RPA are prerequisite for the recruitment of
RAD51 to sites of DNA damage. Accordingly, DHX9 deficient
cells were also greatly impaired in the formation of RAD51 foci in
response to Cpt-induced DNA damage and exhibited reduced
binding of RAD51 to chromatin (Fig. 5a and Supplementary
Fig. 3c). These data, together with our data showing that DHX9
localizes to sites of DNA damage, established that recruitment of
DHX9 at or near to DSB helps to suppress NHEJ and promote
DNA resection.
Although cells depleted of DHX9 were also impaired in the
recruitment of RPA and RAD51 to IR-induced DNA breaks
(Supplementary Fig. 4c–f), this defect was markedly reduced
compared with cells treated with Cpt. This was consistent with
our earlier finding that colocalization of DHX9 with γH2AX is
significantly less in cells damaged with IR. While it is possible that
the pathways for resecting DNA breaks generated by Cpt and IR
might differ in their requirement for DHX9, the difference might
also reflect a greater contribution for NHEJ in the repair of IR-
induced DSB compared with Cpt induced breaks.
Classical resection of DNA ends is initiated by CTIP18,19 and
the MRN (MRE11-RAD50-NBS1) nuclease complex and then
extended in the 5′-3′ direction by EXO1 exonuclease or through a
combination of DNA2 and BLM (reviewed in ref. 20). Therefore
we next determined whether DHX9 was in the same genetic
pathway for DNA resection as CTIP and MRE11. Cpt-induced
recruitment of RPA to foci was greatly reduced in cells knocked
down for CTIP, confirming that the majority of DNA resection is
dependent on the activity of CTIP (Fig. 5b). This was broadly
comparable with the resection defect observed in cells knocked
down for DHX9 (Fig. 5b and Supplementary Fig. 3d). Since the
mean number of RPA foci was not further diminished in cells
depleted of both CTIP and DHX9, we concluded that DHX9 and
CTIP probably function in a common pathway for the generation
of ssDNA. It was previously reported that in cells that are
defective in RNA splicing, impaired DNA end resection may
result from the decreased expression of CTIP21. Importantly, we
confirmed that knockdown of DHX9 did not affect cellular levels
Fig. 1 DHX9 accumulates at sites of DNA damage. a Fluorescence image showing that DHX9 localizes to DNA damage-induced nuclear foci in cells
treated with 1 μM camptothecin for 4 h. Nuclei are stained with Dapi. b Fluorescence images showing that DHX9 (green) co-localizes with γH2AX (red) in
cells treated with 1 μM camptothecin for 4 h but not in cells treated with 10 Gy Ionizing radiation (left panel). Merged images identify co-localized proteins
as staining yellow. Quantification of colocalization of DHX9 and γH2AX treated with 1 μM camptothecin and 10 Gy ionizing radiation (right panel) plotted
as Pearson coefficient. c Localization of camptothecin-induced DHX9 in foci is impaired in cells treated with 10 μM DRB to inhibit transcription. d DHX9
damage-induced foci disintegrate after treatment with RNaseA. Quantification of n cells (as indicated) from three pooled biologically independent
experiments were performed in (b–d). Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test (****p < 0.0001, *p < 0.1).
Mean and error bars indicating one standard deviation are also indicated. Source data are provided as a Source Data file.
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Fig. 2 DHX9 is required for the repair of DNA damage induced by camptothecin and olaparib. a Western blot showing knockdown of DHX9 by two
different siRNAs, DHX9(7) and DHX9(utr) in U2OS cells. GAPDH is indicated as a loading control. b Clonogenic survival assay showing that cells knocked
down for DHX9 are hypersensitive to DNA damage caused by treating cells with camptothecin and c Olaparib. d Graph of percentage cell viability after
treatment of indicated cells with ionizing radiation measured by counting live cells in a Casey Cell counter. Cells depleted of DHX9 exhibit no decrease in
viability compared to wild-type cells. Graphs include data from three biologically independent experiments. Statistical significance was determined using
one-way ANOVA with Tukey’s post hoc test (****p < 0.0001, ****p < 0.0001, ***p < 0.001, *p < 0.1, ns not significant). Mean and error bars indicating one
standard deviation are also indicated. Source data are provided as a Source Data file.
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of CTIP, RAD51, or BRCA1 in our experiments (Supplementary
Fig. 5a).
We then confirmed that MRE11 was also required for the
generation of RPA in response to Cpt-induced DNA damage.
Interestingly, the contribution of MRE11 to the formation of RPA
foci was less than that of either DHX9 or CTIP (Fig. 5b).
Nevertheless, because DNA resection was similar in cells depleted
of both MRE11 and DHX9 to cells impaired in DHX9 alone, we
concluded that MRE11 and DHX9 also function in a common
genetic pathway for DNA resection. Together, these data suggest
that DHX9 is required for classical end-resection of broken DNA
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recruitment of downstream proteins such as RAD51 that are
essential for HR mediated DSB repair.
DHX9 responds to signaling by ATR and ATM. To establish
whether the recruitment of DHX9 in response to Cpt-induced
DNA damage was dependent on DNA damage signaling by the
ATM and ATR kinases, we measured recruitment of DHX9 to
DNA damage in the presence and absence of the ATR and ATM
inhibitors VE-821 and KU55933. This revealed that while DHX9
foci were diminished in cells treated with either ATR or ATM
inhibitors, the effect of inhibiting ATR was greater than inhibiting
ATM (Fig. 5c).
We also looked at the effect of these inhibitors on the
accumulation of RPA as a marker of DNA end resection. In wild-
type cells, inhibition of ATR reduced the formation of RPA foci to
a low level, similar to that observed in cells knocked down for
DHX9 (Fig. 5d). Since knockdown of DHX9 and inhibition of
ATR together caused no further reduction in RPA foci we
inferred that DHX9-mediated end resection responded to the
ATR signaling pathway. A similar relationship was observed in
cells where ATR was knocked down using siRNA instead of with
chemical inhibition (Fig. 5e).
Although knockdown of ATM in U2OS cells also impaired the
generation of RPA foci in response to Cpt-induced DNA damage
(Fig. 5e), this defect was less severe than that caused by depletion
of either DHX9 or ATR. This suggested that ATR may play a
bigger role than ATM to promote DNA end resection in response
to Cpt-induced DNA damage. Nevertheless, knockdown of
DHX9 was epistatic to ATM for the recruitment of RPA,
suggesting that these proteins also function in a common
pathway.
Previous studies have shown that DNA damage signaling by
ATR requires its autophosphorylation on Threonine 198922. To
determine if DHX9 was required for ATR activation we measured
DNA damage-induced autophosphorylation in cells that were
knocked down for DHX9. Whereas, in wild-type cells, Cpt
treatment induced robust phosphorylation of ATR on Threonine
1989, this was greatly diminished in cells depleted for DHX9
(Fig. 5f). Moreover, phosphorylation of Chk1, a downstream
target for ATR, was also diminished. Hence, DHX9 and ATR
work together in a common pathway for the resection of DSB
during HR.
DHX9 interacts with BRCA1 in response to DNA damage. The
repair of DNA breaks by HR is dependent on the mediator
protein BRCA123. Cells that are defective in BRCA1, like those
depleted of DHX9, are impaired in DNA resection and fail to
recruit RAD51 to sites of DNA damage24,25. To establish if
BRCA1 and DHX9 work together in HR we depleted both pro-
teins in U2OS pDR-GFP cells and measured HR mediated DSB
repair. Since the HR defect in cells lacking both BRCA1 and
DHX9 was similar to that of cells knocked down for DHX9 and
BRCA1 individually, we concluded that these two proteins
operate in a common genetic pathway for HR (Fig. 6a). Con-
sistent with this, we also observed significant co-localization of
BRCA1 with DHX9 in DNA-damage-induced foci in cells treated
with Cpt (Fig. 6b).
It was previously reported that recombinant DHX9 binds to a
c-terminal fragment of BRCA1 in GST pull-down experiments
and in a yeast two-hybrid assay8,26. To determine whether
endogenous BRCA1 and DHX9 interact in cells, we immuno-
precipitated DHX9 and looked for co-purification of BRCA1.
Surprisingly, very little endogenous BRCA1 co-
immunoprecipitated with DHX9 in unperturbed cells, suggesting
that there might be limited interaction between DHX9 and
BRCA1 in the absence of DNA damage, or that the interaction is
unstable (Fig. 7a). In contrast, DHX9 and BRCA1 interacted
robustly in cells that were treated with DNA damaging agents
(Cpt, hydroxyurea, and IR). Importantly, co-purification of
BRCA1 with DHX9 was not mediated through RNA as all
immunoprecipitations were performed in the presence of
RNaseA. This indicated that BRCA1 and DHX9 probably interact
prior to their localization at DNA damage. We previously found
that the detection of DHX9 on chromatin was enhanced at
promoter regions and at transcription termination sites at which
RNA Pol II was stalled6. Therefore we speculate that DHX9 and
BRCA1 might interact constitutively, but that detection of this
complex by immunoprecipitation is enhanced when RNA Pol II
is stalled at sites of DNA damage.
DHX9 is thought to bridge the interaction between BRCA1 and
RNA Polymerase II holoenzyme8. We recently showed that
DHX9 promotes the recruitment of various proteins to RNA Pol
II holoenzyme by facilitating their binding to nascent RNA6.
Therefore, we next addressed whether the interaction of BRCA1
and DHX9 with the RNA Pol II holoenzyme was dependent on
RNA. To do this we immunoprecipitated RNA Pol II and
measured the co-purification of DHX9 and BRCA1 in the
presence and absence of RNaseA. While DHX9 and BRCA1 co-
immunoprecipitated with RNA Pol II, BRCA1 was largely absent
in samples that were treated with RNaseA, with only a very small
amount of DHX9 retained (Fig. 7b). This confirmed that the
association of both BRCA1 and DHX9 with RNA Pol II is
mediated primarily through RNA, most likely the nascent strand
formed during RNA Pol II-mediated transcription. Interestingly,
co-purification of BRCA1 and DHX9 with RNA Pol II was
significantly diminished in cells in which either protein was
depleted. This indicated that BRCA1 and DHX9 probably
Fig. 3 DHX9 is required in DSB repair by homologous recombination. a DHX9 deficient cells are proficient in the repair of I-Sce1 induced DSB by non-
homologous end joining (NHEJ). Left panel: NHEJ reporter system in which NHEJ mediated repair of two DSB leads to the deletion of the thymidine kinase
gene enabling expression of GFP (red arrow) from the CMV promotor (green arrow). Right panel: Graph of percentage of cells expressing GFP as a
measure of successful NHEJ. Knockdown of key NHEJ proteins Ku86 and p54nrb in reporter cell line H1299-dA3-1 was performed as a positive control.
Elevated NHEJ in DHX9 deficient cells is suppressed by the expression of siRNA-resistant myc-DHX9 expressed from a plasmid. b U2OS cells knocked
down for DHX9 are deficient in the repair of I-Sce1 induced DSB by recombination (HR) using a pDR-GFP U2OS reporter assay. Left panel: Reporter
measuring HR mediated repair of an I-Sce1 induced DSB in a GFP gene (Sc-GFP) containing multiple stop codons, using homologous sequences in a
defective iGFP gene with 3′ and 5′ terminal deletions. Only repair of the DSB by HR generates an active EGFP gene. Right panel: Cells knocked down for
DHX9 and BRCA1 with different siRNAs. Percent GFP-expressing cells are shown. c HR-mediated DSB repair requires the helicase activity of DHX9.
Overexpression of siRNA resistant myc-tagged wild-type DHX9, but not helicase “dead” mutant DHX9 restores HR mediated repair to cells knocked down
with siRNA DHX9(utr) targeted against the non-translated region of DHX9. Knockdown of 53BP1 in DHX9 defective cells does not restore HR. In (a), (b),
and (c) mean values from n= 3 independent experiments are shown to be statistically significant using one-way ANOVA test with Tukey’s post hoc
analysis (ns not significant, *p < 0.1, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Error bars of 1 SD are also indicated. Source data are provided as a Source
Data file.
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associate with RNA Pol II holoenzyme as a single preformed
complex and that both proteins are required for its binding to
RNA. This hypothesis was supported by fluorescence images
showing that the recruitment of BRCA1 to Cpt-induced DNA
damage foci was diminished in cells knocked down for DHX9
(Fig. 7c). Moreover, the recruitment of the complex was
dependent on the unwinding activity of DHX9 since over-
expression wild type but not helicase dead DHX9 mutant protein
partially restored BRCA1 foci (Supplementary Fig. 5b). The
accumulation of BRCA1 in damage-induced foci, like those of
DHX9, was greatly also diminished in cells treated with RNase A
indicating that recruitment of BRCA1 in Cpt-induced foci is
siCntrl
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dependent on RNA (Fig. 7c). Lastly, the recruitment of DHX9
and BRCA1 in nuclear foci was suppressed by treating cells with
the transcription inhibitor DRB (5,6-dichloro-1-β-D-ribofurano-
sylbenzimidazole) (Supplementary Fig. 5c).
Therefore, our data support a model in which BRCA1 and
DHX9 are recruited to sites of DNA damage as a preformed
complex that binds to nascent RNA generated by RNA Pol II-
mediated transcription where they facilitate the repair of DNA
damage by HR.
DHX9 contributes mechanistically to HR. Previous studies
established that the HR defect in BRCA1-deficient cells is sup-
pressed by knockdown or mutation of the end-joining proteins
53BP1 and RIF127–29. While DNA end resection is severely
impaired in BRCA1 defective cells, it occurs at almost normal
levels in BRCA1−/−53BP1−/− cells28. Similarly, cells that are
defective in BRCA1 alone are hypersensitive to Olaparib, while
cells deficient in both BRCA1 and 53BP1 are resistant. Therefore,
while BRCA1 is an important mediator of the HR pathway, it
does not perform a mechanistic role in HR-mediated DSB repair.
Instead, BRCA1 channels DSB for HR repair by suppressing
53BP1-mediated DNA end-joining. This process is referred to as
pathway choice.
The suppression of NHEJ by BRCA1 is achieved, at least in
part, by its ability to inhibit the recruitment of RIF1 to sites of
DNA damage29. Therefore, we looked to see whether the same
was true for DHX9. We first confirmed that the treatment of cells
with IR resulted in the recruitment of RIF1 to punctate nuclear
foci. Although RIF1 was also recruited to chromatin after
treatment of cells with Cpt, this staining was less punctate, most
likely reflecting the different mechanism through which Cpt and
IR induce DNA damage. Nevertheless, depletion of DHX9 led to
an increased accumulation of RIF1 on chromatin in response to
Cpt (Fig. 8a). This was consistent with our earlier finding that
cells that are deficient in DHX9 exhibit increased levels of DSB
repair by NHEJ. Importantly, it confirmed that like BRCA1,
DHX9 suppresses the recruitment of Rif1 to chromatin during
pathway choice.
If the sole function of DHX9 in HR is to facilitate recruitment
of BRCA1 to inhibit 53BP1-mediated end joining, one might
expect that it would be dispensable for HR in cells simultaneously
knocked down for 53BP1. However, this was not the case (Fig. 8).
Simultaneous knockdown of DHX9 and 53BP1 caused only a
small increase in the generation of RPA foci (Fig. 8b) and a partial
suppression of HR in a pDR-GFP DSB repair assay (Fig. 3c).
siDHX9si53BP1 double knockdown cells also remained hyper-
sensitive to Olaparib treatment (Fig. 8c). This indicated that, in
addition to its role in pathway choice, DHX9 also contributes
mechanistically to HR.
What then might this role be? One possibility was that DHX9
promoted the recruitment and function of proteins that are
directly involved in DNA resection. To address this we treated
cells with Cpt and measured the recruitment of the resection
proteins CTIP and BLM to chromatin. Interestingly, in cells
depleted of DHX9, recruitment of both CTIP and BLM to nuclear
foci in response to Cpt was diminished (Fig. 9a, b). Consistent
with this observation, CTIP and BLM were reduced in the
chromatin fraction of cell extracts prepared from DHX9 depleted
cells (Fig. 9c). From this, we concluded that, in addition to its role
in pathway choice, DHX9 enhanced the recruitment and/or
stability of CTIP and BLM on chromatin during DNA end
resection.
DHX9 is required for DNA damage-induced replication
restart. In the absence of pathway choice, CTIP mediated DNA
resection can occur independently of BRCA1. However, we
observed that the defect in resection of Cpt-induced DSB in both
BRCA1 defective and DHX9 defective cells was only partially
suppressed by knockdown of 53BP1. Previously, BRCA1 was
hypothesized to play a role in the processing of DNA ends that
are blocked and, therefore, refractory to DNA replication. These
might include DNA ends terminating in top Icc or ends con-
taining chain terminating nucleotides30,31. In the absence of
BRCA1, these blocked DNA ends are less permissive for the
restart of DNA synthesis that is critical for their repair.
Mohiuddin et al.30 demonstrated further that resumption of DNA
synthesis for DNA ends containing chain-terminating nucleotides
required a pathway that was dependent on the interaction of
BRCA1 with CtIP. Importantly this function of BRCA1 was
independent of 53BP1 and pathway choice.
Since DHX9 delivers BRCA1 to Cpt-induced DSB, we
predicted that it might also contribute to the processing of top
Icc end intermediates to facilitate DNA replication. To address
this we modified the assay of Mohiuddin et al.30 for Cpt-induced
DSB. We incubated cells for 30 min in media containing the
nucleotide analog CldU to enable its incorporation into
the genomes of replicating cells. CldU was washed out from the
media and the cells were incubated for 2 h in fresh media
containing 5 μM Cpt to induce DSB. After removal of the drug,
we incubated cells for a further 1 h in fresh media containing a
second nucleotide analog, IdU. The incorporation of these
nucleotides into DNA was detected using specific antibodies
and visualized by fluorescence imaging. Cells that were under-
going DNA replication before Cpt treatment were identified by
the incorporation of CldU into DNA. Cells that were permissive
for DNA replication after Cpt treatment were identified by the
additional incorporation of IdU.
Wild-type cells were proficient for replication restart after Cpt
treatment and therefore incorporated both IdU (green) and CldU
(red), appearing mainly yellow when images were merged. As
expected, cells knocked down for BRCA1 were impaired in
replication restart and therefore exhibited fewer yellow cells and
more cells incorporating IdU alone (green) (Fig. 9d). Importantly,
we confirmed that this defect was not suppressed by the
simultaneous knockdown of 53BP1 and was therefore indepen-
dent of pathway choice. Critically, the same was true for cells
Fig. 4 DHX9 is required in DNA end-resection. a Fluorescent image (left panel) with quantification (right panel) showing similar levels of γH2AX foci in
siControl (red) and siDHX9 (blue) cells treated with 1 μM camptothecin for 2 h. b Fluorescent image (left panel) with quantification (right panel) showing
formation of RPA foci in siControl (red) and siDHX9 (blue) cells treated with 1 μM camptothecin for 2 h then recovered without the drug for the indicated
times. DHX9 defective cells are impaired in formation of RPA foci. c RPA foci are dependent on the helicase activity of DHX9 and are diminished in cells
overexpressing siRNA resistant helicase GFP-DHX9 dead mutant. Cells were treated with 1 μM camptothecin for 2 h. Quantification of n cells (as indicated)
from three pooled biologically independent experiments were performed in (a), (b), and (c). Mean and error bars for one standard deviation are shown.
Data sets were shown to be significantly different using a one-way ANOVA test with Tukey’s post hoc analysis as described in Methods. (ns not
significant, *p < 0.1, **p < 0.01, ***p < 0.001, and ****p < 0.0001). d Western blot showing reduced RPA in the chromatin (P1) fraction of cells treated with
1 μM camptothecin (2 h) and knocked down for DHX9. RPA in the cytoplasmic (S1) and nucleoplasm (S2) fractions is not affected by the knockdown of
DHX9. Lamin A/C is shown as a control for nuclear fractionation. Source data are provided as a Source Data file.
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knocked down for DHX9. Significantly fewer of these cells were
competent for DNA synthesis after treatment with Cpt and
therefore primarily stained green. This defect was not suppressed
by a loss of 53BP1. From this, we concluded that DHX9 plays an
important role in the restart of DNA synthesis in response to
Cpt-induced DNA damage. We hypothesize that DHX9, along
with BRCA1 and CTIP, processes top Icc blocked DNA ends
making them permissive for DNA end resection and for repair
synthesis in a reaction that is independent of pathway choice.
Together, our data argue that DHX9 is a key component in the
DDR, linking transcription with the processing and resection of
broken DNA ends for HR.
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Discussion
Current understanding of how DHX9 contributes to the main-
tenance of genomic instability has focussed on its ability to
unwind unusually stable nucleic acid secondary structures that
occur throughout the human genome6,12,13. We show here that
DHX9 also plays a critical and direct role in the repair of DSB by
HR. We demonstrate that DHX9 functions early in HR to pro-
mote the processing and resection of broken DNA ends, gen-
erating the 3′ ssDNA substrate for RAD51 recombinase to drive
HR. Moreover, we establish that this function is dependent on the
direct physical interaction of DHX9 with BRCA1 and that,
together, these proteins associate with the RNA Pol II holoen-
zyme mediated through RNA. Our findings identify DHX9 as a
key component of the DDR, linking RNA processing with the
repair of DNA breaks.
Like many DDR proteins, DHX9 accumulates at sites of DNA
damage. DHX9 accumulates efficiently to DSB induced by
treating cells with Cpt but is recruited to IR induced DSB much
less frequently. Accordingly, cells that are defective for DHX9 are
hypersensitive to treatment with Cpt, but not to IR. This suggests
that DHX9 is recruited to and is required for the repair of a
specific subset of DSB, rather than all breaks. What then defines
this group of breaks? The majority of breaks generated by Cpt-
induced inhibition of top I are thought to arise through
transcription-replication collisions (TRC) that occur when DNA
replication encounters trapped or stalled RNA Pol II complexes.
These TRC are reasonably common but are greatly elevated in
precancerous and tumor cells.
Since DHX9 is a component of the RNA Pol II holoenzyme we
speculate that it primarily accumulates at DSB that occur in
transcribed regions of the genome. This is supported by our data
showing that the recruitment of DHX9 to Cpt-induced foci is
dependent on both transcription and on RNA. While IR-induced
DSB may also occur at transcribed loci, these breaks are generated
by direct scission of DNA strands and not by TRC. Consequently,
IR-induced DSB are more likely to comprise canonical two-ended
DSB that are an efficient substrate for repair by NHEJ. Collapsed
replication forks arising from TRC, by contrast, are more likely to
generate SEB that requires homologous recombination for their
repair.
This link to transcription also explains why Cpt-induced
DHX9 foci become more intense over time. We speculate that
DNA breaks in regions of high transcription will lead, over time,
to an accumulation of RNA Pol II and therefore also DHX9 at the
break site. Accordingly, persistent DSB become more intensely
stained for DHX9. Interestingly, the accumulation of DHX9 at
DSB also coincides with the generation of DNA-RNA hybrid.
This is consistent with our previous study showing that DHX9
promotes the generation of R-loops at sites of stalled or trapped
RNA Pol II and argues against the alternative hypothesis that
Fig. 5 DHX9 is required for the recruitment of RAD51. a Fluorescent image (left panel) and quantification (right panel) showing the decreased formation
of RAD51 foci in control U2OS cells (red) and cells knocked down for DHX9 (blue) treated with 1 μM camptothecin for 2 h then left for 2 h to recover.
b DHX9 is in a common genetic pathway for the formation of RPA foci with CTIP and MRE11. RPA foci in cells knocked down using siRNA for the indicated
genes are shown. Cells were treated with 1 μM camptothecin for 2 h. c Recruitment of DHX9 to foci is dependent on ATM and ATR. Wild-type cells were
inhibited for ATR and ATM using VE-821 and KU55933, respectively. d, e DHX9 is in a common genetic pathway for the formation of RPA foci with ATR
and ATM. RPA foci are shown for cells treated with inhibitors for ATR (VE-821) and ATM (KU55933) (d) or knocked down with siRNA against ATM and
ATR (e). f Western blot showing that knockdown of DHX9 impairs Cpt induced autophosphorylation of ATR on Thr1989 and phosphorylation of Chk1 on
ser 345. Quantification of n cells (as indicated) from three pooled biologically independent experiments were performed in (a–e). Means of data sets were
shown to be significantly different using one-way ANOVA with Tukey’s post hoc test. (ns not significant, *p < 0.1, **p < 0.01, ***p < 0.001, and ****p <



















































































Fig. 6 DHX9 and BRCA1 function in the same genetic pathway. a BRCA1 and DHX9 are in the same genetic pathway for the repair of an I-Sce1 induced
DSB by HR measured in a pDR-GFP assay. Data were from three independent experiments. Statistical significance was established using a one-way
ANOVA with post hoc Tukey’s test (****p < 0.0001). b Fluorescence images of BRCA1 (red) and DHX9 (green) co-localize in DNA Damage induced
nuclear foci. The graph depicts the Pearson coefficient for co-localization of DHX9 and BRCA1 in untreated cells and cells treated with 1 μM camptothecin
for 2 h. Differences in mean values for three independent experiments were shown to be statistically significant using a one-way t-test (****p < 0.0001).
Error bars indicating one standard deviation are also indicated. Source data are provided as a Source Data file.
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DHX9 removes R-loops. Nevertheless, it is currently unclear
whether these R-loops are simply by-products of transcriptional
pausing or whether they are generated as obligate intermediates
in DSB repair.
Rapid repair of DNA damage at expressed loci is critical for the
preservation of normal cell function. A paradigm for the pre-
ferential removal of DNA damage from expressed genes exists for
transcription-coupled nucleotide excision repair32. In cells, a
similar coupling of transcription with DSB repair would confer
significant benefits for the maintenance of genomic stability. In
support of such a pathway, Aymard et al. reported that DSB
located in transcribed loci are preferentially repaired by RAD51-
dependent HR, while DSB in silent chromatin showed no pre-
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model for transcription-associated homologous recombination
repair (TA-HRR) in which R loops recruit RAD52 and BRCA1 to
initiate HR and suppress recruitment of RIF1-53BP1 for NHEJ33.
Notwithstanding these and other models, the pivotal roles of
DHX9 in RNA Pol II-dependent transcription and HR suggest it
is likely to play a key role in any pathway for transcription-
associated DSB repair. Central to its HR function is the associa-
tion of DHX9 with BRCA1. Previous studies reported that
BRCA1 and DHX9 interact even in the absence of DNA
damage26. However, we detected only a low-level interaction in
unperturbed cells. In contrast, the formation of the BRCA1-
DHX9 complex was significantly increased in cells exposed to
various DNA damaging agents, including IR. One possibility is
that in the original nonphysiological experiments, overexpression
of individual domains of BRCA1 and DHX9 in yeast two-hybrid
and GST pull-down experiments alleviated the requirement for
Fig. 7 BRCA1 and DHX9 form a complex that interacts with RNA Pol II-mediated through RNA. a Western blot showing co-immunoprecipitation of
BRCA1 with DHX9 in cells treated with DNA damaging agents; 2 mM hydroxyurea (for 4 h), 2 μM camptothecin (for 2 h), and ionizing radiation (10 Gy) (as
indicated). All samples were treated with RNaseA to exclude interactions mediated by RNA. b Western blot of RNA Pol II immunoprecipitation from U2OS
cells knocked down for specific genes using siRNAs indicated and treated with 1 μM camptothecin for 2 h (all samples). Blot shows co-purification of
BRCA1 and DHX9 with RNA Pol II is dependent on the presence of both DHX9 and BRCA1 in cells. Co-precipitation of DHX9 and BRCA1 with RNA Pol II is
also dependent on RNA as the interaction is disrupted in samples treated with RNaseA (indicated). c Fluorescence image (left panel) with quantification
(right panel) showing that DNA damage-induced BRCA1 foci are diminished in cells knocked down for DHX9 and in cells treated with RNaseA. Graph (right
panel) shows the quantification of n cells (as indicated) from three pooled biologically independent experiments. Mean values were shown to be
significantly different using one-way ANOVA with post hoc Tukey’s test (****p < 0.0001). Mean and standard deviation are shown. Source data are










































































































































Fig. 8 Defects in DHX9 are not suppressed by knockdown of 53BP1. a DHX9 suppresses the recruitment of RIF1 to chromatin in response to
camptothecin-induced DNA damage. The intensity of chromatin-bound RIF1 staining is plotted. Mean and standard deviation are indicated. b Defect in the
recruitment of RPA into foci in DHX9 defective cells is only partially restored by knockdown of 53BP1. A number of RPA foci is plotted for cells knocked
down for the indicated genes using siRNA. Quantification of n cells (as indicated) from three pooled biologically independent experiments were performed
in (a) and (b). c Knockdown of 53BP1 does not restore Olaparib resistance to DHX9 depleted cells in a clonogenic survival assay (left panel) but does
restore Olaparib resistance to BRCA1 defective cells (right panel). The data sets for DHX9 and BRCA1 were performed concurrently, with the same
controls, but are depicted separately for presentation purposes. Survival values were quantified from n= 3 biologically independent experiments. (a–c)
Statistical analysis performed using one-way ANOVA and multiple comparisons analysed using post hoc Tukey’s test in (a) and (b). (ns not significant, *p
< 0.1, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Means and error bars indicating one standard deviation are also indicated. Source data are provided as a
Source Data file.
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DNA damage. Alternatively, it is possible that DHX9 and BRCA1
interact constitutively, but that the complex is enriched or sta-
bilized in cells with high levels of stalled of RNA Pol II, enhancing
its detection.
The interaction of DHX9 with BRCA1 is mediated through the
carboxy-terminal region of BRCA1 containing the BRCT
domains26. A number of other important complexes are formed
by proteins that bind to the BRCT domains of BRCA1, including
several that are implicated in the resection of DSB. These include
ABRAXAS, BRIP1, and CTIP proteins that bind the BRCT
domains of BRCA1 to form the BRCA1-A34, BRCA1-B35, and
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nomenclature on BRCT domain-interacting complexes, BRCA1-
DHX9 might be named BRCA1-D. Unfortunately, however, this
name has been used to describe the interaction of BRCA1 in a
complex with PALB2, BRCA2, and KEAP137. Therefore, we
subsequently refer to BRCA1-DHX9 as BRCA1-DX.
The formation of the BRCA1-DX complex is essential for its
recruitment to RNA Pol II and for its role in HR. DHX9 protein
was previously reported to act as a bridge for the interaction of
BRCA1 with RNA Pol II through direct protein–protein
contacts8,26. Our data reveal a critical role for RNA in the
recruitment of BRCA1-DX to RNA Pol II with only a small
contribution from protein–protein interactions. This explains
why DNA damage-induced BRCA1 and DHX9 foci are sensitive
to treatment with RNaseA. In vitro, BRCA1 binds weakly to
DNA38,39 whereas DHX9 binds to both RNA and DNA. In cells,
DHX9 did not associate with RNA Pol II in the absence of
BRCA1. Hence, BRCA1 and DHX9 are incorporated into the
RNA Pol II holoenzyme as a preformed complex that binds
nascent RNA. Intriguingly, this raises the possibility that BRCA1
contributes to other functions involving DHX9, for example
during co-transcriptional processing of pre-mRNA. This
hypothesis is supported by a recent report where overexpression
of the RNA splicing associated oncogene EWS-FLI1, a known
interactor of DHX9, caused BRCA1 to become trapped on
chromatin with RNA Pol II in the absence of exogenous DNA
damage40. Interestingly these cells are also defective in HR,
highlighting the potential of DHX9 to link transcription with the
repair of DNA damage by HR.
Our data suggest a model where RNA Pol II delivers BRCA1-
DX to DNA damage to promote DNA end resection and
recruitment of RPA to DNA (Supplementary Fig. 5d). Previous
studies showed that BRCA1 facilitates end resection by stimulating
the activity of CTIP41,42. This is consistent with our genetic data
showing that DHX9 and CTIP operate in a common pathway that
responds to the DNA damage signaling kinases ATR and ATM.
Accordingly, we demonstrated that the stable recruitment of both
CTIP and BLM to damaged chromatin is less efficient in the
absence of DHX9. We speculate that, by recruiting BRCA1 to
DSB, DHX9 promotes CTIP function and facilitates the formation
of the BRCA1-C complex, which together with MRN initiates
DNA end-resection. Likewise, the ability of DHX9 to enhance the
recruitment of BLM might increase the processivity of DNA
resection. Subsequent turnover of BRCA1-C and the formation of
the BRCA1-A complex is thought to modulate the overall extent
of this resection43,44. Hence the sequential assembly of these
interrelated complexes is potentially an important mechanism to
regulate resection and the repair of DSB by HR. How the for-
mation and resolution of various BRCA1 complexes are orche-
strated will be important to establish in the future.
The relationship between DHX9 function and DNA damage
signaling is intriguing. Our data suggest that DHX9 responds to
damage signaling by the ATR kinase and less so to ATM. This is
not surprising since Cpt-induced DSB are likely generated by
replication stress, which is a known substrate for ATR signaling.
Depletion of either ATR or DHX9 result in severely decreased
end resection and defective HR. However, our data suggest that it
is not the case that ATR simply signals for downstream activation
of DHX9 in DSB repair. DHX9 also stimulates autopho-
sphorylation of ATR that promotes damage signaling. In the
absence of DHX9, we detected a significant reduction in the
phosphorylation of Chk1. Hence the activities of DHX9 and ATR
are potentially interdependent. By acting very early in HR, DHX9
might promote the recruitment of other proteins via the tran-
scription complex that are required for ATR activation. Further
studies will be required to determine how this might occur.
It is not yet clear whether BRCA1-DX is recruited to RNA Pol
II during normal transcription or whether its recruitment
involves the expression of DDR RNAs (DDRNA) that are
induced in the vicinity of DNA damage, as proposed for
recruitment of 53BP1 and MDC13. DDRNAs are thought not to
play a role in the initial detection of DNA damage but are needed
instead for the secondary recruitment of DDR factors through a
mechanism that is currently unknown45,46. BRCA1-DX on the
other hand has the potential to act very early in the DDR where it
could signal the presence of DSB at transcribed loci by coupling
the initiation of DNA end resection to the slowing or pausing of
transcription complexes as they encounter DNA damage26. This
is not unprecedented as BRCA1, together with another RNA
helicase SENATAXIN (SETX), has been shown to promote the
repair of R-loop associated DNA damage at transcriptional pause
sites47. It is possible, therefore, that BRCA1-DX and BRCA1/
SETX are manifestations of the same, or similar, transcription-
dependent repair activities.
It is clear that DHX9 plays an important role in HR during
pathway choice. Like BRCA1, DHX9 promotes HR by suppres-
sing the recruitment of RIF1 to DNA damage thereby preventing
53BP1 mediated end-joining29. However, while both DNA end
resection and HR are restored to BRCA1 defective cells in which
53BP1 has been knocked out, this was not the case for DHX9.
Instead, siDHX9si53BP1 double knockdown cells were sensitive
to Olaparib and impaired for DNA end resection, indicating that
the contribution of DHX9 to HR is not limited to the establish-
ment of pathway choice. One potential contribution of DHX9,
that lies downstream of pathway choice, is its ability to promote
the recruitment of the resection proteins CTIP and BLM as
described above. Both proteins are required mechanistically for
HR, independent of pathway choice (that is, in cells in which
neither BRCA1 nor 53BP1 is functional).
Although, in the absence of pathway choice, CTIP mediated
end resection of “naked” DSB occurs independently of BRCA1,
the interaction of BRCA1 and CTIP is essential for the repair of
DSB with blocked termini. It has been hypothesized that this
Fig. 9 DHX9 promotes the recruitment of CTIP and BLM to DNA damage. a Fluorescence images (left panel) and graph (right panel) showing that
localization of BLM to camptothecin-induced DNA damage foci is impaired in cells knocked down for DHX9. b Fluorescence images (left panel) and graph
(right panel) showing that localization of CTIP to camptothecin-induced DNA damage foci is impaired in cells knocked down for DHX9. Quantification of n
cells (as indicated) from three pooled biologically independent experiments were performed in (a) and (b). Means were shown to be significantly different
using one-way ANOVA with post hoc Tukey’s test (****p < 0.0001). c Western blot of fractionated cell extracts showing that localization of BLM and CTIP
to chromatin (P1 fraction) in response to camptothecin-induced DNA damage is reduced in cells knocked down for DHX9. Localization of BLM and CTIP in
cytoplasmic (S1) and nuclear fractions (S2) is not decreased. Histone H3 is shown as a marker of S2 and P1 fractions. d DNA synthesis is impaired in DHX9
and BRCA1 deficient cells treated with camptothecin (5 μM for 2 h). This defect is not suppressed by knockdown of 53BP1 Right panel shows representative
images for the incorporation of CldU and IdU nucleotide analogs as well as merged images. The left panel shows graphical data of cells stained with both
CldU and IldU as a percentage of total cells stained with CldU. Graphs include data from three biologically independent experiments. Mean and error bars
indicating one standard deviation are also indicated. Statistical significance for all experiments was demonstrated using one-way ANOVA with post hoc
Tukey’s test (****p < 0.0001, *p < 0.1, ns not significant). Source data are provided as a Source Data file.
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includes DNA breaks that are blocked by the presence of Cpt-
induced Top Icc31. It is likely that processing of Top Icc blocked
ends involves endonucleolytic cleavage at or near the DNA ter-
minus by CTIP and/or MRE11 and in contrast to the generation
of ssDNA by resection, this activity requires BRCA1. However,
the biochemical mechanism for this function has not been
established. Our data demonstrate that this pathway also requires
DHX9 and raises the question of whether it occurs exclusively at
DSB associated with stalled transcription or whether it also
operates in the repair of other blocked DNA ends. Nevertheless,
the contribution of DHX9 to this function cannot be suppressed
by mutation or loss of 53BP1 and is therefore independent of
pathway choice. Moreover, it highlights the multifunctional
contribution of DHX9 in HR.
Our understanding of how RNA and transcription contributes
to the repair of DNA damage is still emerging and a subject of
great interest. The present work adds DHX9 to a growing number
of RBP that have been implicated in the maintenance of genome
stability and the repair of DNA breaks. Importantly, we have
shown how DHX9 links RNA and RNA Pol II to the repair of
DSB and the restart of DNA replication through the formation of
the BRCA1-DX complex. Our demonstration that BRCA1-DX,
like BRCA1-A and BRCA1-C, plays a pivotal role in DNA end
resection highlights the importance of this step in the regulation
of DSB repair and uncovers a key contribution played by RNA in
the repair of DNA damage by HR.
Methods
Cell culture. HeLa and U2OS cell lines were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 5
% ampicillin. HeLa and U2OS cell lines were obtained from ATCC, H1299-dA3-1
was a kind gift of Professor Takashi Kohno (National Cancer Center Research
Institute. Tokyo, Japan)
Antibodies, chemicals, and reagents. Primary antibodies used in this study and
concentrations used for immunoprecipiatation (IP), immunofluorescence (IF), and
Western blot (WB) are indicated. Rabbit polyclonal anti-RNA Helicase A
(ab26271, Abcam, for IP 5 µg/ml, IF 1:1000, and WB 1:2000 dilution), mouse
monoclonal anti-BRCA1 antibody (OP92, Ab-1; Calbiochem, for IPs 10 μg/ml, IF
1:250, and WB 1:200 dilution), mouse anti-RPA32 (RPA2 Ab #2; Calbiochem, IF
1:500, WB 1:1000, and for FACS 1:100 dilution), rabbit polyclonal anti-RNA-
Polymerase II (N-20; Santa Cruz Biotechnology, IP 4 μg/ml and WB 1:1000 dilu-
tion), mouse monoclonal anti-GAPDH antibody (GT239; GeneTex, WB 1:1000
dilution), mouse monoclonal anti-phospho-Histone H2A.X (clone JBW301; EMD
Millipore, IF 1:250 dilution and WB 1:500 dilution), rabbit anti-phospho-Histone
H2A.X (ab81299, Abcam, IF 1:1000 dilution), rabbit polyclonal anti-Rad51 anti-
body (H-92; Santa Cruz Biotechnology, IF 1:250 dilution), rabbit polyclonal anti-
53BP1 Antibody (NB100-904; Novus Biologicals, IF 1:500, WB 1:2000), rabbit
polyclonal anti-53BP1 Antibody (A300-272A, Universal biologicals, IF 1:1000
dilution), mouse monoclonal Anti-BrdU antibody (B44; BD Biosciences, 1:1000
dilution for IF), Rat monoclonal anti-BrdU antibody (ab6326, Abcam, IF 1:1000
dilution), rabbit polyclonal anti-CTIP antibody (NB100-79810, Novus Biologicals,
WB 1:2000, IF 1:500 dilution), rabbit polyclonal anti-MRE 11 antibody (NB100-
142, Novus Biologicals, WB 1:1000 dilution), rabbit polyclonal anti-BLM antibody,
(PLA0029, Sigma-Aldrich, WB 1:1000 dilution), mouse monoclonal anti-ATR
antibody (NB100-308, Novus Biologicals,WB 1:1000 dilution), rabbit polyclonal
anti-ATM antibody (NB100-104, Novus Biologicals, WB 1:1000 dilution), rabbit
monoclonal anti-Ku80 Antibody (218, Cell Signaling, WB 1:1000 dilution). Sec-
ondary antibodies: goat anti-mouse Alexa Fluor 488 and 647 (Molecular Probes)
was used at 1:200 dilution for FACS and 1:1000 dilution for IF, goat anti-rabbit
Alexa fluor 488, 568, and 647 (Molecular Probes) was used at 1:1000 dilution for
IF, goat anti-rat Alexa 488-conjugated secondary antibody (Molecular Probes, IF
1:600 dilution), goat anti-mouse Alexa 594 conjugated secondary antibody
(Molecular Probes, IF 1:500 dilution).
Secondary antibodies for western blot; Peroxidase-AffiniPure Goat Anti-Rabbit
IgG (H+ L) 111-035-144-JIR (1:5000 dilution) and Mouse IgG antibody (HRP)
(GTX213111-01; GeneTex, 1:5000 dilution) were used. IgG controls were Normal
Rabbit IgG #2729 (Cell Signaling) and normal mouse IgG (sc-2025; Santa Cruz
Biotechnology).
Chemicals; Hydroxyurea H8627 and (S)-(+ )-Cpt C9911 (Sigma-Aldrich),
AZD 2281- Olaparib (Axon Medchem), 5-Bromo-2′-deoxyuridine (Sigma, B5002),
VE-821 (Sigma, SML 1415), RNase A 19101 (17,500 U, Qiagen), Ribonuclease H
(Thermofischer, 18021014), Halt™ Protease Inhibitor Cocktail (100X) 78429
(Thermos Scientific) and PhosSTOP™ (Merck), 5-Chloro-2′-deoxyuridine (C6891,
Sigma-Aldrich), 5-Iodo-2′-deoxyuridine (17125, Sigma-Aldrich).
Plasmids. pMyc-DHX9 was a kind gift of Prof. Jerry Pelletier (McGill University,
Canada), pGFP-DHX9 was purchased from Stratech. pMyc-DHX9dead and pGFP-
DHX9dead containing D511A and E512A mutations were made by site-directed
mutagenesis using Q5 site-directed mutagenesis system (New England Biolabs)
according to the manufacturer’s instructions.
SiRNA. The siRNAs were purchased from Dharmacon-ON-TARGET plus. Non-
targeting siRNA Control- D-001810-01-05; DHX9- J-009950-07, DHX9utr- CTM-
310164, and CTM-478066; 53BP1- J-003548-07; BRCA1- J-003461-09, ATR- L-
003202-00, ATM- L-0030201-00, CTIP- J-011376-07, MRE11A- J-009271-07, and
XRCC5 (Ku86)- J-010491-08-0005. SiRNA mediated knockdown of genes was
performed using Lipofectamine RNA MAX (Invitrogen) according to the manu-
facturer’s instructions. Knockdown of different proteins was confirmed by western
blot (Supplementary Fig. 6).
Homologous recombination assay by FACS. About 75,000 U2OS cells containing
the pDR-GFP reporter gene were plated in a six-well plate overnight and trans-
fected with siRNA. After 48 h 2 µg of the I-Sce1 expression vector pCBASce was
transfected into cells. After a further 48 h cells were harvested and the number of
GFP-positive cells was measured by FACS (Fortessa- BD Biosciences). For com-
plementation experiments, a plasmid expressing a wild type of mutant DHX9 was
transfected simultaneously with incubation of siRNA.
Nonhomologous end-joining assay by FACS. H1299dA3-1 cells were knocked
down for indicated genes using siRNA as above and grown for 48 ho. About 50,000
cells were seeded in a 12-well plate and transfected with 1 µg pCBASce plasmid
DNA using X-tremeGENE™ HP DNA Transfection Reagent (XTGHP-RO, Roche)
and grown for a further 48 h. Cells were harvested by trypsinization, washed with
PBS, and GFP expressing cells quantified using FACS (Fortessa cytometer- BD
Biosciences). All experiments were performed as three or more biological
replicates.
Immunoprecipitation. Prior to immunoprecipitation, the primary antibody was
incubated with Dynabeads protein G beads (Invitrogen) overnight at 4 °C. Cells
were lysed using Lysis Buffer (150 mM NaCl, 0.5% Triton X-100, 50 mM Tris-HCl
pH 7.5, NaCl, 1 mM EDTA, 5% glycerol, and 0.1% SDS) supplemented with
protease and phosphatase inhibitor cocktails (Thermo Scientific). Lysed cells were
passed through a 23 G needle ten times on ice and incubated for 30 min at 4 °C
with shaking. For BRCA1, 500 mM NaCl was included in the lysis buffer. Where
indicated 3 μl of RNaseA was added to 1 ml of extract and incubated at 37 °C
for 30 min. The supernatant was cleared by high-speed centrifugation at 16,000xg
at 4 °C in a benchtop microcentrifuge. The cleared lysate (1 mg) was added to the
antibody-Dynabead complex and incubated at 4 °C with rotation for between 4 and
12 h. Immunocomplexes were separated using a magnet, washed three times in
lysis buffer, boiled in sample buffer, and loaded on a 4–12% Bis-Tris poly-
acrylamide gel (Invitrogen). Proteins were transferred to the PVDF membrane
using a Novex transfer system (Invitrogen) and immunoblotted using the indicated
antibodies.
Fluorescence imaging. U2OS cells were seeded on coverslip overnight, non-
chromatin bound proteins were pre-extracted using 0.5% TritonX-100 CSK buffer
(25 mM Hepes pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mMMgCl2, 300 mM sucrose)
for 2–5 min on ice and then fixed with 3.7% paraformaldehyde. For RNase A
treatment, cells were either treated for 30 min at room temperature before or after
fixation with RNase A (200 µg in 500 μl Phosphate buffered saline (PBS)). Cells
were washed three times in PBS and permeabilized for 10 min in 0.5% Triton X-
100/PBS. After three additional PBS washes, cells were blocked using 1–3% BSA/
PBS for 30 min. Cells were incubated with primary antibody (as indicated above),
followed by the addition of Alexa Fluor-488 or -568 or 647 conjugated secondary
antibodies (1:1000). To visualize nuclei, cells were also stained with 0.5 μg/ml DAPI
(Molecular Probes) for 15 min. Slides were mounted using Prolong gold anti-fade
reagent (Invitrogen) and images were acquired using a Delta vision DV4 wide-field
deconvolution microscope with a 100X objective. Where indicated, cells were
treated with 1 µM Cpt and incubation for various times, after which cells were
washed with PBS, pre-permeabilized, fixed, and processed as above.
Cells were seeded on coverslips and grown overnight and then transfected with
siRNA for 6 h the media changed and then cells grown for a further 48 h. Where
indicated plasmid expressing wild-type DHX9 or D511A E512A helicase “dead”
mutant was transfected using lipofectamine 2000 reagent (Invitrogen) for 48 h.
Images were analyzed using a Delta Vision microscope and quantified using Image
J software.
Image Analysis- Colocalization between X protein and Y protein was assessed
in single-cell regions using SoftWoRx (version 5.5.0, release 6). A rectangular
selection was defined for each cell in deconvolved images and the Pearson
coefficient of correlation was calculated for the volume. A custom-designed macro
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24341-z
16 NATURE COMMUNICATIONS |         (2021) 12:4126 | https://doi.org/10.1038/s41467-021-24341-z | www.nature.com/naturecommunications
for quantifying nuclear foci was developed by the Dundee Imaging Facility. This
was used to quantify nuclear foci in two different channels (green and red). Nuclei
were automatically detected in the DAPI channel using the Default ImageJ auto-
thresholding method and foci in the red and green channels were counted using
ImageJ’s “Find Maxima” feature with a user-defined Prominence above the
background.
ssDNA detection assay by immunofluorescence. Cells were grown on micro-
scope slides overnight. siRNA knockdown was performed as above and cells were
incubated with 10 µM BrdU 24 h. A total of 1 µM Cpt was added to the media for
2 h and then washed out with PBS. Cells were pre-permeabilized in ice for 5 mins
then fixed and treated as above using non-denaturing conditions. Cells were
incubated with primary antibody against BrdU overnight then washed and sec-
ondary antibody added as above. Images were captured with a Delta vision DV4
wide-field deconvolution microscope using a 40x objective.
Cell viability assay. U2OS cells were transfected with siRNA for 48 h as above.
About 5000 cells per well were seeded into a 12-well plate (time 0). On days 3 and
7, cells were recovered from the monolayer using trypsin and viable cells counted
using Casey Cell Counter. Where indicated Cpt and Olaparib were included in the
medium and replenished every 3 days. Cell viability was plotted using data from
three to six independent biological replicates.
Clonogenic survival assay. Cells were seeded into six-well plates at a density of
1000 cells per well treated with drugs at the indicated concentrations. After
incubation for 7 to 10 days, cells were fixed and stained with a 0.05% solution of
crystal violet in methanol, containing 1% formaldehyde. The absorbed dye was
resolubilized with methanol containing 0.1% SDS for 2 h, 100 µl of which was
transferred into 96-well plates and measured photometrically (595 nm) in a
microplate reader. Data were representative of three independent experiments.
Flow cytometry. Analysis of RPA staining by FACS was performed as previously
described with a few modifications48. Firstly, non-chromatin bound proteins were
extracted with 0.5% Triton X-100 (PBS-T) for 15 min on ice followed by fixation in
4% paraformaldehyde and then permeabilized for 30 min at room temperature.
After washing in PBS the cells were incubated with primary and secondary anti-
body subsequently, washed and stained with 0.02% sodium azide, 250 μg/ml RNase
A and 2 μg/ml of 4′,6-diamidino-2-phenylindole (DAPI) in PBS for at least 30 min
at 4 °C prior to analysis using a Fortessa flow cytometer (Beckton Dickinson). Data
were collected from more than three independent experiments and quantified
using Prism v6 (GraphPad Software). Analysis of cell cycle was performed as
described previously6.
Cell fractionation. Briefly, 3 × 106 HeLa cells per condition were collected and
suspended in 250 µl of buffer A (10 mM HEPES pH 7.8, 10 mM KCl, 1.5 mM
MgCl2, 0.25M sucrose, 10% glycerol, 1 mM Dithiothreitol (DTT), 0.1% Triton-X-
100, protease, and phosphatase inhibitors) and incubated for 5 min on ice. The
soluble cytoplasmic fraction (S1) was separated from the nuclei (P2) by cen-
trifugation for 4 min at 1700×g at 4 °C. The nuclear fraction P2 was washed twice
with 500 µl buffer A and suspended in 200 µl buffer B (3 mM EDTA, 0.2 mM
EGTA, 1 mM DTT, phosphatase, and protease inhibitors) and incubated at 4 °C for
30 min. The insoluble chromatin fraction (P1) was separated from the nuclear
soluble proteins (S2) pellet by acid-extraction using 0.25 N HCl and incubated on
ice for 30 min. The lysate was then centrifuged at 16,000xg for 15 min at 4 °C. The
supernatant (contains acid-soluble proteins) was neutralized using 1 M Tris-HCl
pH 8 using 1:5 volume. Twenty-five micrograms of the protein were loaded in
4–12% Bis-Tris gradient polyacrylamide gel and transferred onto the PVDF
membrane (Millipore). Membranes were blocked in PBS with 0.1% Tween 20 and
probed with respective primary antibodies. Bound proteins were detected with
Pierce ECL western blotting substrates and developed with x-ray film (Konica
Minolta).
Replication restart assay. Hela cells were grown on slides and pulse-labeled for
30 min with 50 μM of CldU. Cells were washed with PBS and then treated with 5
μM of Cpt for 2 hrs, washed with PBS and incubated with fresh medium. Cells were
then grown in media containing 50 μM of IdU for 60 mins. Cells were then washed
and fixed in 4% paraformaldehyde for 15 min and then permeabilized in 0.5%
Triton X-100 for 15 min. Cells were incubated with 2M HCl for 45 min to
denature the DNA and then blocked for 30 min with 5% milk in PBS-T. To
visualize CldU, cells were immunostained for 1 h with rat primary monoclonal
antibody against BrdU [BU1/75, Abcam], washed with 0.05% PBS-T 20 and three
times for 5 min then immunolabeled for 30 min with goat anti-rat Alexa 488-
conjugated secondary antibody (Molecular Probes). To visualize IdU cells were
immunostained for 40 mins at 4 °C with mouse anti-BrdU monoclonal antibody
(Becton Dickinson). Cells were subsequently labeled for 30 min with goat anti-
mouse Alexa 594 conjugated secondary antibody (Molecular Probes) to label IdU.
Replication restart is represented by the co-localization of CldU and IdU. Nuclei
were counterstained with DAPI for fluorescence imaging.
Data processing, statistical analysis, and reproducibility. For scatter graphs,
data from n cells (as indicated) from three pooled independent experiments were
plotted. Mean and error bars representing one standard deviation are shown. Data
were analyzed and, where appropriate, the significant differences between the mean
values of independent data sets was determined using one-way ANOVA test with
ad hoc Tukey’s test for multiple comparisons (*p < 0.1, **p < 0.01, ***p < 0.001,
****p < 0.0001), as indicated. For these populations, prior to ANOVA, we also
established that there were significant differences in the dependent variable using a
non-parametric two-tailed Mann–Whitney unpaired t-test (not shown). All sta-
tistics were performed using Prism v9 (GraphPad Software). Micrographs and
western blots represent results from three or greater biologically independent
experiments.
Reporting Summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Any additional reasonable requests for data
supporting the findings of this study are available from the corresponding author. Source
data are provided with this paper.
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